On-Demand CME Videos
FC24: The Comorbidities of Psoriasis: What Clinicians Need to Know to Optimize Care: An Online Activity
About
The Comorbdities of Psoriasis: What Clinicians Need to Know to Optimize Care: An Online Activity
This activity is supported by educational grants from Amgen and Lilly, USA, LLC.
Availability
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
December 12, 2024
December 12, 2025
Learning Objectives
At the completion of this activity, participants should be better able to:
Review the immunopathologic mechanism of psoriatic disease and associated comorbidities
List key therapies to manage psoriatic disease and associated comorbidities
Select optimal therapies for psoriasis patients based on demographics, comorbidities, and medical history
Describe effective strategies for multidisciplinary care of patients with psoriasis and related co-morbidities
Intended Audience
Faculty
Joel Gelfand, MD, MSCE, FAAD
Penn Medicine
Director, Psoriasis and Phototherapy Treatment Center
Director, Center for Clinical Sciences in Dermatology
Philadelphia, Pennsylvania
Karan Lal, DO, MS, FAAD
Director of Pediatric and Cosmetic Dermatology
Affiliated Dermatology
Scottsdale, AZ
Bruce Strober, MD, PhD
Clinical Professor of Dermatology Yale University
Department of Dermatology
New Haven, CT
Central Connecticut Dermatology
Cromwell, CT
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada, Reno School of Medicine and CMEsquared. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Nevada, Reno School of Medicine designates this enduring activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
No relevant financial relationships with any Ineligible Company in the past 24 months.
Advisory Board: Incyte, Galderma, Aphyn Biologics, Verrica, Cerave
Speaker's Bureau or Honoraria: Abbvie, Galderma, Incyte, Boehringer, Verrica
Consultant: AbbVie, Alumis, Almirall, Amgen, Arcutis, Arena, Aristea, Asana, Boehringer Ingelheim, Immunic Therapeutics, Bristol-Myers-Squibb, Connect Biopharma, Dermavant, EPI Health, Evelo Biosciences, Janssen, Leo, Eli Lilly, Maruho, Meiji Seika Pharma, Mindera Health, Novartis, Pfizer, UCB Pharma, Sun Pharma, Regeneron, Sanofi-Genzyme, Union Therapeutics, Ventyxbio, vTv Therapeutics
Speakers’ Bureau or Honoraria: AbbVie, Eli Lilly, Incyte, Janssen, Regeneron, Sanofi-Genzyme
Scientific Co-Director (consulting fee): CorEvitas (formerly Corrona) Psoriasis Registry
Investigator: Dermavant, AbbVie, CorEvitas Psoriasis Registry, Dermira, Cara, Novartis
Editor-in-Chief (honorarium): Journal of Psoriasis and Psoriatic Arthritis
Ownership Interest: Connect Biopharma
The University of Nevada, Reno School of Medicine discloses that all relevant conflicts have been satisfactorily mitigated.